Literature DB >> 33411760

Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro.

Annemiek Dickhout1, Bibian M E Tullemans1, Johan W M Heemskerk1, Victor L J L Thijssen2, Marijke J E Kuijpers1, Rory R Koenen1,3.   

Abstract

Galectin-1 (gal-1) is a carbohydrate-binding lectin with important functions in angiogenesis, immune response, hemostasis and inflammation. Comparable functions are exerted by platelet factor 4 (CXCL4), a chemokine stored in the α-granules of platelets. Previously, gal-1 was found to activate platelets through integrin αIIbβ3. Both gal-1 and CXCL4 have high affinities for polysaccharides, and thus may mutually influence their functions. The aim of this study was to investigate a possible synergism of gal-1 and CXCL4 in platelet activation. Platelets were treated with increasing concentrations of gal-1, CXCL4 or both, and aggregation, integrin activation, P-selectin and phosphatidyl serine (PS) exposure were determined by light transmission aggregometry and by flow cytometry. To investigate the influence of cell surface sialic acid, platelets were treated with neuraminidase prior to stimulation. Gal-1 and CXCL4 were found to colocalize on the platelet surface. Stimulation with gal-1 led to integrin αIIbβ3 activation and to robust platelet aggregation, while CXCL4 weakly triggered aggregation and primarily induced P-selectin expression. Co-incubation of gal-1 and CXCL4 potentiated platelet aggregation compared with gal-1 alone. Whereas neither gal-1 and CXCL4 induced PS-exposure on platelets, prior removal of surface sialic acid strongly potentiated PS exposure. In addition, neuraminidase treatment increased the binding of gal-1 to platelets and lowered the activation threshold for gal-1. However, CXCL4 did not affect binding of gal-1 to platelets. Taken together, stimulation of platelets with gal-1 and CXCL4 led to distinct and complementary activation profiles, with additive rather than synergistic effects.

Entities:  

Year:  2021        PMID: 33411760      PMCID: PMC7790394          DOI: 10.1371/journal.pone.0244736

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  63 in total

1.  Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A(2) pathways.

Authors:  Ban B Dawood; Jonathan Wilde; Steve P Watson
Journal:  Platelets       Date:  2007-08       Impact factor: 3.862

2.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

3.  Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII.

Authors:  Jamie M O'Sullivan; P Vince Jenkins; Orla Rawley; Kristina Gegenbauer; Alain Chion; Michelle Lavin; Barry Byrne; Richard O'Kennedy; Roger J S Preston; Teresa M Brophy; James S O'Donnell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-24       Impact factor: 8.311

Review 4.  Galectins: their network and roles in immunity/tumor growth control.

Authors:  Herbert Kaltner; Stefan Toegel; Gabriel García Caballero; Joachim C Manning; Robert W Ledeen; Hans-Joachim Gabius
Journal:  Histochem Cell Biol       Date:  2016-12-24       Impact factor: 4.304

Review 5.  Chemokines and thrombogenicity.

Authors:  Michele P Lambert; Bruce S Sachais; M Anna Kowalska
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 6.  Glycans and the platelet life cycle.

Authors:  Renhao Li; Karin M Hoffmeister; Hervé Falet
Journal:  Platelets       Date:  2016-05-02       Impact factor: 3.862

7.  Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.

Authors:  Don E Eslin; Chunyan Zhang; Kathleen J Samuels; Lubica Rauova; Li Zhai; Stefan Niewiarowski; Douglas B Cines; Mortimer Poncz; M Anna Kowalska
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

8.  Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release.

Authors:  S Sehgal; B Storrie
Journal:  J Thromb Haemost       Date:  2007-07-23       Impact factor: 5.824

9.  Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity.

Authors:  Thi-Huong Nguyen; Nikolay Medvedev; Mihaela Delcea; Andreas Greinacher
Journal:  Nat Commun       Date:  2017-05-22       Impact factor: 14.919

Review 10.  Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities.

Authors:  Ignacio M Seropian; Germán E González; Sebastián M Maller; Daniel H Berrocal; Antonio Abbate; Gabriel A Rabinovich
Journal:  Mediators Inflamm       Date:  2018-11-05       Impact factor: 4.711

View more
  4 in total

Review 1.  Galectin 1-A Key Player between Tissue Repair and Fibrosis.

Authors:  Anca Hermenean; Daniela Oatis; Hildegard Herman; Alina Ciceu; Giovanbattista D'Amico; Maria Consiglia Trotta
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  Chemokines modulate glycan binding and the immunoregulatory activity of galectins.

Authors:  Lucía Sanjurjo; Iris A Schulkens; Pauline Touarin; Roy Heusschen; Ed Aanhane; Kitty C M Castricum; Tanja D De Gruijl; Ulf J Nilsson; Hakon Leffler; Arjan W Griffioen; Latifa Elantak; Rory R Koenen; Victor L J L Thijssen
Journal:  Commun Biol       Date:  2021-12-20

3.  Combined Antiplatelet Therapy Reduces the Proinflammatory Properties of Activated Platelets.

Authors:  Alexandra C A Heinzmann; Daniëlle M Coenen; Tanja Vajen; Judith M E M Cosemans; Rory R Koenen
Journal:  TH Open       Date:  2021-10-28

Review 4.  Galectokines: The Promiscuous Relationship between Galectins and Cytokines.

Authors:  Lucía Sanjurjo; Esmee C Broekhuizen; Rory R Koenen; Victor L J L Thijssen
Journal:  Biomolecules       Date:  2022-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.